“Being at least as good as the leader is a prerequisite to being competitive.”
— Peter Drucker

 Among the various uses for the Patent Asset Index™, one major area of application is in portfolio Benchmarking. Any company operating in the modern day sets goals for themselves, to guide them towards the success that they strive to achieve. Our unparalleled data quality and multi-pronged analysis tools ensure that decision makers get the right information at the right time to make decisions about the right goals to set.  

In a newly released whitepaper PatentSight takes a deep dive into the portfolio of Palantir – one of Silicon Valley’s most secretive companies – to demonstrate how advanced patent analytics can be used to provide critical insights for investment decisions.

Ranked among the top 10 global medical device companies as of revenue, General Electric is now about to file for an IPO to spin out its health-care unit GE Healthcare, as reported by CNBC. With the ongoing jump of Siemens Healthineers shares after their $5 Billion IPO, now GE Healthcare has caught the attention of investors in the medical device market. In this context, PatentSight shed light on the global top 10 medical device companies as of revenue in 2017 from a patent perspective.

 跳转到简体中文 (jump to Simplified Chinese)：

中国高校创新力前20强

As of today effective drugs for Alzheimer’s and Parkinson’s diseases are missing. In fact, Pharma giant Pfizer recently announced that they’re ending their research in this field. Which from an innovation analytics point of view does not come as a complete surprise.

You may have seen our recent press release but I wanted to personally express my excitement over the recent acquisition by LexisNexis® IP. We anticipate that as a result of this acquisition, we will be able to make significant enhancements to our product.

With added content, financial resources, and a broader customer base we will significantly accelerate our development. In particular, the advent of powerful self-learning algorithms often described as “artificial intelligence” is a great opportunity to reach the next breakthrough in patent analytics. We are thrilled to leverage our competence in high quality data and reliable science-based algorithms to continue leading the field with advanced tools that offer unique and reliable business insights.

Rest assured, many things you value about PatentSight will not change. PatentSight will continue under the leadership of myself and my team in the same offices in Bonn, Germany. All PatentSight employees will be retained and your current points of contact will not change. Our much-praised Consulting & Support Team will continue to serve you directly. The name of the product will change slightly to LexisNexis PatentSight.

We look forward to our continued relationship. Please contact me, Björn Ulmer or your main contact in the business development team if you have any additional questions.